Background Patient characteristics and survival outcomes in randomized trials may be
different from those in real-life clinical practice. The objective of this study was to describe …

Background: This retrospective register study assessed overall survival (OS) and influential
factors on OS in Swedish renal cell carcinoma (RCC) patients. Methods: Using three merged …

Conclusions The results of the currently used targeted drugs demonstrate perspectives of
metastatic RCC conservative treatment, that are able to prolong cancer–specific survival in …

Background Immuno-oncology (IO) agents and tyrosine kinase inhibitors (TKIs) have
revolutionized the treatment paradigm for metastatic renal cell carcinoma (mRCC). Data on …

PURPOSE: S8949 demonstrated improved overall survival for debulking nephrectomy in
interferon treated patients with advanced renal cell carcinoma. We present an updated …

Defining rational follow-up guidelines in patients treated for cancer is important, from both a
medical and an economical perspective. Renal-cell carcinoma is reputed to be …

Opinion statement In general, debulking neprhectomy is still considered for metastatic RCC
patients with primary tumor in place, assuming good performance status. Initial systemic …

Background This retrospective study investigated overall survival (OS) and factors
influencing OS in Swedish patients with metastatic renal cell carcinoma (mRCC) during the …

The landscape of local and systemic therapy of renal cell carcinoma (RCC) is rapidly
changing. The increase in the incidental finding of small renal tumors has increased the …

In Switzerland efficient availability of novel drugs for renal cell cancer (RCC) has been
granted early. Since the advent of the targeted agents for RCC the usage of these drugs has …